Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: real-world data

ConclusionsThe overall SVR12 rates in our study were comparable with those in previous pivotal trials. DAAs are generally safe. The interaction of HBV and HCV during DAA therapy and the observation of de novo HCC development and HCC recurrence during or after DAAs warrants additional studies.
Source: Journal of Microbiology, Immunology and Infection - Category: Microbiology Source Type: research